5 Key Takeaways

• 1

  A cohort study of 45.7 million adults in England assessed the cardiovascular safety of COVID-19 vaccines from December 2020 to January 2022.

• 2

  The study found a generally lower incidence of cardiovascular events following COVID-19 vaccination, with some rare exceptions.

• 3

  Rare adverse events included vaccine-induced thrombotic thrombocytopenia after ChAdOx1 and myocarditis and pericarditis after mRNA vaccinations.

• 4

  Adjusted hazard ratios indicated lower rates of arterial and venous thrombotic events after vaccination with various doses and brands.

• 5

  The study's strengths included a large sample size and comprehensive analysis, while limitations involved potential residual confounding.